Debashis Ghosh
Concepts (848)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Expression Profiling | 56 | 2025 | 1817 | 4.870 |
Why?
| | Leishmaniasis, Visceral | 18 | 2026 | 24 | 4.740 |
Why?
| | Data Interpretation, Statistical | 28 | 2020 | 371 | 4.410 |
Why?
| | Models, Statistical | 44 | 2024 | 680 | 4.330 |
Why?
| | Algorithms | 41 | 2025 | 1843 | 3.970 |
Why?
| | Oligonucleotide Array Sequence Analysis | 38 | 2016 | 765 | 3.280 |
Why?
| | Computational Biology | 21 | 2025 | 683 | 2.630 |
Why?
| | Computer Simulation | 36 | 2024 | 1032 | 2.540 |
Why?
| | Machine Learning | 10 | 2024 | 573 | 2.470 |
Why?
| | Psychodidae | 7 | 2023 | 8 | 2.170 |
Why?
| | Biomarkers, Tumor | 25 | 2022 | 1327 | 2.110 |
Why?
| | Metabolomics | 9 | 2022 | 721 | 2.070 |
Why?
| | Biometry | 13 | 2011 | 68 | 2.040 |
Why?
| | Software | 16 | 2025 | 690 | 2.000 |
Why?
| | Prostatic Neoplasms | 28 | 2024 | 977 | 1.820 |
Why?
| | Retinol-Binding Proteins | 5 | 2016 | 16 | 1.710 |
Why?
| | Eye Proteins | 6 | 2016 | 92 | 1.650 |
Why?
| | Neoplasms | 25 | 2024 | 2902 | 1.580 |
Why?
| | Regression Analysis | 13 | 2021 | 1003 | 1.420 |
Why?
| | Phlebotomus | 5 | 2023 | 5 | 1.410 |
Why?
| | Leishmaniasis, Cutaneous | 4 | 2024 | 14 | 1.400 |
Why?
| | Genomics | 12 | 2024 | 834 | 1.290 |
Why?
| | Neoplasm Proteins | 12 | 2018 | 443 | 1.270 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2023 | 1075 | 1.250 |
Why?
| | Models, Biological | 14 | 2021 | 1833 | 1.230 |
Why?
| | Proportional Hazards Models | 11 | 2023 | 1305 | 1.210 |
Why?
| | Gene Expression Regulation, Neoplastic | 24 | 2021 | 1496 | 1.200 |
Why?
| | Humans | 202 | 2026 | 143817 | 1.200 |
Why?
| | Statistics, Nonparametric | 8 | 2019 | 431 | 1.100 |
Why?
| | Biomarkers | 14 | 2021 | 4248 | 1.100 |
Why?
| | Causality | 4 | 2022 | 126 | 1.090 |
Why?
| | Bangladesh | 15 | 2026 | 60 | 1.090 |
Why?
| | Databases, Factual | 12 | 2024 | 1459 | 1.080 |
Why?
| | Diagnostic Imaging | 2 | 2022 | 334 | 1.070 |
Why?
| | Insecticides | 4 | 2023 | 42 | 1.040 |
Why?
| | Biostatistics | 3 | 2014 | 19 | 1.030 |
Why?
| | Insect Control | 4 | 2023 | 18 | 1.030 |
Why?
| | Insect Vectors | 4 | 2023 | 39 | 1.020 |
Why?
| | Image Processing, Computer-Assisted | 8 | 2024 | 787 | 1.020 |
Why?
| | Aromatase | 2 | 2019 | 32 | 0.970 |
Why?
| | Endemic Diseases | 2 | 2024 | 33 | 0.960 |
Why?
| | Survival Analysis | 12 | 2024 | 1358 | 0.960 |
Why?
| | Meta-Analysis as Topic | 4 | 2014 | 170 | 0.890 |
Why?
| | Natural Gas | 1 | 2025 | 26 | 0.890 |
Why?
| | Oil and Gas Fields | 1 | 2025 | 33 | 0.880 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 293 | 0.870 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 738 | 0.850 |
Why?
| | Microscopy | 3 | 2023 | 157 | 0.840 |
Why?
| | Magnetoencephalography | 2 | 2021 | 160 | 0.830 |
Why?
| | Lung Neoplasms | 7 | 2023 | 2636 | 0.830 |
Why?
| | Leishmania donovani | 5 | 2022 | 12 | 0.820 |
Why?
| | Colonic Neoplasms | 2 | 2022 | 262 | 0.810 |
Why?
| | Histological Techniques | 1 | 2023 | 39 | 0.800 |
Why?
| | Environmental Exposure | 3 | 2025 | 584 | 0.780 |
Why?
| | Models, Genetic | 11 | 2019 | 533 | 0.770 |
Why?
| | Genetic Association Studies | 5 | 2019 | 375 | 0.770 |
Why?
| | Multivariate Analysis | 16 | 2022 | 1508 | 0.760 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 445 | 0.750 |
Why?
| | Zebrafish Proteins | 2 | 2016 | 311 | 0.740 |
Why?
| | Pyrethrins | 1 | 2021 | 8 | 0.710 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 360 | 0.710 |
Why?
| | Connectome | 2 | 2021 | 90 | 0.710 |
Why?
| | Cognitive Dysfunction | 4 | 2021 | 451 | 0.690 |
Why?
| | Mass Spectrometry | 6 | 2022 | 747 | 0.690 |
Why?
| | Parkinsonian Disorders | 1 | 2021 | 42 | 0.690 |
Why?
| | Brain Mapping | 2 | 2021 | 535 | 0.670 |
Why?
| | Brain | 4 | 2024 | 2901 | 0.670 |
Why?
| | Housing | 2 | 2021 | 145 | 0.660 |
Why?
| | Endpoint Determination | 2 | 2011 | 82 | 0.650 |
Why?
| | Cluster Analysis | 12 | 2024 | 530 | 0.640 |
Why?
| | Nitriles | 1 | 2021 | 204 | 0.640 |
Why?
| | Propensity Score | 4 | 2018 | 359 | 0.640 |
Why?
| | Phenotype | 12 | 2023 | 3182 | 0.630 |
Why?
| | Feasibility Studies | 2 | 2024 | 1065 | 0.620 |
Why?
| | Clinical Trials as Topic | 4 | 2022 | 1047 | 0.610 |
Why?
| | Placenta | 2 | 2019 | 778 | 0.610 |
Why?
| | Risk Assessment | 8 | 2020 | 3556 | 0.600 |
Why?
| | Databases, Genetic | 11 | 2021 | 249 | 0.600 |
Why?
| | High-Throughput Screening Assays | 2 | 2012 | 174 | 0.600 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 121 | 0.590 |
Why?
| | Learning | 1 | 2023 | 447 | 0.590 |
Why?
| | Genetic Variation | 4 | 2019 | 990 | 0.590 |
Why?
| | Quantitative Trait, Heritable | 2 | 2018 | 117 | 0.580 |
Why?
| | DNA Copy Number Variations | 2 | 2017 | 185 | 0.580 |
Why?
| | Metadata | 1 | 2018 | 16 | 0.570 |
Why?
| | Metabolome | 1 | 2021 | 383 | 0.540 |
Why?
| | Cardiovascular Diseases | 5 | 2022 | 2098 | 0.540 |
Why?
| | Protein Conformation | 4 | 2015 | 933 | 0.540 |
Why?
| | Logistic Models | 12 | 2020 | 2095 | 0.540 |
Why?
| | Glioma | 1 | 2022 | 424 | 0.530 |
Why?
| | Male | 77 | 2026 | 71568 | 0.530 |
Why?
| | Transcriptome | 2 | 2023 | 1047 | 0.530 |
Why?
| | Reproducibility of Results | 17 | 2021 | 3392 | 0.520 |
Why?
| | Epidemiologic Methods | 2 | 2007 | 92 | 0.510 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1688 | 0.510 |
Why?
| | Immunohistochemistry | 11 | 2022 | 1733 | 0.510 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 1178 | 0.500 |
Why?
| | Markov Chains | 7 | 2017 | 125 | 0.470 |
Why?
| | Registries | 2 | 2024 | 2242 | 0.460 |
Why?
| | Sensitivity and Specificity | 12 | 2024 | 1984 | 0.460 |
Why?
| | Linear Models | 7 | 2018 | 857 | 0.460 |
Why?
| | Female | 63 | 2026 | 77569 | 0.450 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2016 | 162 | 0.450 |
Why?
| | Crystallography, X-Ray | 7 | 2019 | 484 | 0.450 |
Why?
| | Empirical Research | 2 | 2012 | 21 | 0.440 |
Why?
| | Bayes Theorem | 7 | 2022 | 427 | 0.430 |
Why?
| | Case-Control Studies | 10 | 2025 | 3614 | 0.430 |
Why?
| | Protein Folding | 1 | 2016 | 283 | 0.430 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2017 | 646 | 0.430 |
Why?
| | Diagnosis, Computer-Assisted | 4 | 2008 | 92 | 0.420 |
Why?
| | Autism Spectrum Disorder | 2 | 2017 | 431 | 0.410 |
Why?
| | Lupus Nephritis | 2 | 2025 | 71 | 0.410 |
Why?
| | Nerve Net | 3 | 2024 | 277 | 0.410 |
Why?
| | Statistics as Topic | 3 | 2025 | 279 | 0.410 |
Why?
| | Neuroendocrine Tumors | 3 | 2024 | 111 | 0.400 |
Why?
| | Genome-Wide Association Study | 7 | 2018 | 1446 | 0.390 |
Why?
| | Spectrometry, Fluorescence | 4 | 2016 | 165 | 0.390 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 2019 | 167 | 0.390 |
Why?
| | Bias | 5 | 2022 | 205 | 0.390 |
Why?
| | India | 6 | 2023 | 216 | 0.380 |
Why?
| | Tissue Array Analysis | 3 | 2008 | 51 | 0.370 |
Why?
| | Disease Progression | 15 | 2021 | 2871 | 0.370 |
Why?
| | Treatment Outcome | 9 | 2023 | 11459 | 0.370 |
Why?
| | Oncogenes | 1 | 2013 | 121 | 0.360 |
Why?
| | HIV Infections | 6 | 2026 | 3048 | 0.360 |
Why?
| | Herpes Zoster Vaccine | 2 | 2025 | 154 | 0.360 |
Why?
| | Sulfhydryl Compounds | 1 | 2014 | 189 | 0.350 |
Why?
| | Animals | 33 | 2025 | 38140 | 0.350 |
Why?
| | Genome | 5 | 2017 | 304 | 0.340 |
Why?
| | Insecticide-Treated Bednets | 3 | 2021 | 7 | 0.340 |
Why?
| | Cardiac Catheterization | 1 | 2015 | 531 | 0.340 |
Why?
| | Nerve Tissue Proteins | 4 | 2023 | 600 | 0.340 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2590 | 0.330 |
Why?
| | Monocytes | 2 | 2025 | 543 | 0.320 |
Why?
| | Supervised Machine Learning | 2 | 2021 | 22 | 0.320 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2019 | 2167 | 0.320 |
Why?
| | Alzheimer Disease | 3 | 2015 | 614 | 0.320 |
Why?
| | Herpes Zoster | 2 | 2025 | 315 | 0.320 |
Why?
| | Precision Medicine | 2 | 2025 | 450 | 0.320 |
Why?
| | Adenocarcinoma | 4 | 2017 | 927 | 0.320 |
Why?
| | Principal Component Analysis | 2 | 2023 | 199 | 0.320 |
Why?
| | Middle Aged | 37 | 2026 | 35629 | 0.320 |
Why?
| | Aged | 31 | 2026 | 25616 | 0.310 |
Why?
| | Models, Neurological | 2 | 2024 | 253 | 0.310 |
Why?
| | Child, Preschool | 9 | 2025 | 11631 | 0.310 |
Why?
| | Antioxidants | 1 | 2014 | 580 | 0.310 |
Why?
| | Gene Expression | 3 | 2014 | 1512 | 0.310 |
Why?
| | Colorado | 6 | 2025 | 4578 | 0.310 |
Why?
| | Endoplasmic Reticulum | 1 | 2012 | 266 | 0.300 |
Why?
| | Stem Cells | 3 | 2020 | 622 | 0.300 |
Why?
| | Epidemiologic Research Design | 1 | 2009 | 27 | 0.300 |
Why?
| | Gene Dosage | 1 | 2010 | 148 | 0.300 |
Why?
| | Ki-67 Antigen | 2 | 2020 | 122 | 0.300 |
Why?
| | Signal Transduction | 10 | 2025 | 5241 | 0.300 |
Why?
| | Chromatin Immunoprecipitation | 3 | 2017 | 140 | 0.290 |
Why?
| | Risk Factors | 14 | 2025 | 10623 | 0.290 |
Why?
| | Child | 16 | 2025 | 22441 | 0.280 |
Why?
| | Bone Marrow Transplantation | 2 | 2008 | 294 | 0.280 |
Why?
| | Protein Array Analysis | 8 | 2009 | 58 | 0.280 |
Why?
| | Carcinoma | 2 | 2007 | 230 | 0.280 |
Why?
| | Liver Neoplasms | 1 | 2015 | 774 | 0.280 |
Why?
| | Proteomics | 5 | 2009 | 1192 | 0.280 |
Why?
| | Racemases and Epimerases | 5 | 2006 | 11 | 0.280 |
Why?
| | Statistical Distributions | 1 | 2008 | 8 | 0.270 |
Why?
| | Probability | 3 | 2021 | 305 | 0.270 |
Why?
| | Chromosome Mapping | 6 | 2017 | 511 | 0.270 |
Why?
| | Emigration and Immigration | 1 | 2008 | 64 | 0.270 |
Why?
| | Exercise | 3 | 2026 | 2196 | 0.270 |
Why?
| | DNA-Binding Proteins | 7 | 2018 | 1493 | 0.260 |
Why?
| | DNA Methylation | 4 | 2023 | 673 | 0.260 |
Why?
| | Arrhythmias, Cardiac | 2 | 2020 | 351 | 0.260 |
Why?
| | Research Design | 5 | 2021 | 1121 | 0.260 |
Why?
| | Flow Cytometry | 2 | 2022 | 1192 | 0.250 |
Why?
| | Adult | 28 | 2026 | 40128 | 0.250 |
Why?
| | Tumor Burden | 1 | 2008 | 321 | 0.250 |
Why?
| | Disease Eradication | 1 | 2026 | 5 | 0.240 |
Why?
| | Entropy | 2 | 2023 | 42 | 0.240 |
Why?
| | Proteome | 3 | 2007 | 510 | 0.240 |
Why?
| | Pancreas | 2 | 2020 | 335 | 0.240 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 252 | 0.240 |
Why?
| | High-Intensity Interval Training | 1 | 2026 | 39 | 0.230 |
Why?
| | Monte Carlo Method | 4 | 2017 | 155 | 0.230 |
Why?
| | Diabetes Mellitus | 5 | 2022 | 1088 | 0.230 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2019 | 220 | 0.230 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2025 | 26 | 0.230 |
Why?
| | Neoplasm Staging | 6 | 2019 | 1453 | 0.220 |
Why?
| | Cell Proliferation | 5 | 2021 | 2540 | 0.220 |
Why?
| | False Positive Reactions | 4 | 2012 | 126 | 0.220 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 559 | 0.220 |
Why?
| | Amino Acid Sequence | 3 | 2016 | 2148 | 0.220 |
Why?
| | Adolescent | 13 | 2026 | 22233 | 0.220 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 108 | 0.220 |
Why?
| | Homeodomain Proteins | 4 | 2020 | 524 | 0.220 |
Why?
| | Cell Nucleus | 2 | 2019 | 619 | 0.220 |
Why?
| | Replication Origin | 1 | 2004 | 21 | 0.220 |
Why?
| | Herpesvirus 3, Human | 2 | 2025 | 333 | 0.220 |
Why?
| | Coinfection | 1 | 2026 | 135 | 0.220 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2025 | 179 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 5 | 2023 | 2407 | 0.210 |
Why?
| | Fever | 2 | 2023 | 311 | 0.210 |
Why?
| | Viral Nonstructural Proteins | 1 | 2024 | 67 | 0.210 |
Why?
| | Magnetic Resonance Imaging | 5 | 2022 | 3834 | 0.210 |
Why?
| | Weather | 1 | 2024 | 42 | 0.210 |
Why?
| | Dengue Virus | 1 | 2024 | 58 | 0.210 |
Why?
| | Data Curation | 1 | 2024 | 20 | 0.210 |
Why?
| | Leukemia | 1 | 2006 | 246 | 0.200 |
Why?
| | Carrier Proteins | 2 | 2007 | 750 | 0.200 |
Why?
| | Ligands | 2 | 2016 | 674 | 0.200 |
Why?
| | Antigens | 1 | 2005 | 349 | 0.200 |
Why?
| | ROC Curve | 5 | 2020 | 607 | 0.200 |
Why?
| | Dengue | 1 | 2024 | 89 | 0.200 |
Why?
| | Melanoma | 3 | 2005 | 806 | 0.200 |
Why?
| | Cell Phone | 1 | 2024 | 80 | 0.200 |
Why?
| | Sample Size | 3 | 2008 | 122 | 0.200 |
Why?
| | Histones | 4 | 2020 | 655 | 0.200 |
Why?
| | Coculture Techniques | 1 | 2004 | 250 | 0.200 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2019 | 1123 | 0.200 |
Why?
| | Staining and Labeling | 1 | 2023 | 148 | 0.190 |
Why?
| | Common Variable Immunodeficiency | 1 | 2023 | 28 | 0.190 |
Why?
| | Skin Diseases, Parasitic | 1 | 2022 | 3 | 0.190 |
Why?
| | Recurrence | 5 | 2023 | 1122 | 0.190 |
Why?
| | Membrane Transport Proteins | 1 | 2004 | 154 | 0.190 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 481 | 0.190 |
Why?
| | Carcinogens | 1 | 2003 | 123 | 0.190 |
Why?
| | Organometallic Compounds | 1 | 2023 | 115 | 0.190 |
Why?
| | Neoplasms, Experimental | 1 | 2003 | 172 | 0.190 |
Why?
| | Young Adult | 12 | 2026 | 13914 | 0.190 |
Why?
| | Personality | 1 | 2004 | 132 | 0.190 |
Why?
| | DNA, Complementary | 4 | 2007 | 278 | 0.190 |
Why?
| | Emphysema | 1 | 2023 | 115 | 0.190 |
Why?
| | Biomedical Research | 2 | 2025 | 709 | 0.180 |
Why?
| | Social Stigma | 1 | 2024 | 150 | 0.180 |
Why?
| | Retina | 2 | 2016 | 321 | 0.180 |
Why?
| | Neuroimaging | 2 | 2015 | 286 | 0.180 |
Why?
| | Parasites | 1 | 2022 | 44 | 0.180 |
Why?
| | Body Composition | 1 | 2026 | 715 | 0.180 |
Why?
| | Estrogens | 2 | 2019 | 377 | 0.180 |
Why?
| | Construction Materials | 1 | 2021 | 18 | 0.180 |
Why?
| | Promoter Regions, Genetic | 3 | 2009 | 1255 | 0.180 |
Why?
| | Breast Neoplasms | 7 | 2014 | 2497 | 0.170 |
Why?
| | Leishmania | 1 | 2021 | 3 | 0.170 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 499 | 0.170 |
Why?
| | Infant | 3 | 2024 | 9886 | 0.170 |
Why?
| | Exercise Therapy | 1 | 2026 | 465 | 0.170 |
Why?
| | Brain Waves | 1 | 2021 | 46 | 0.170 |
Why?
| | Polymorphism, Genetic | 1 | 2004 | 618 | 0.170 |
Why?
| | Analysis of Variance | 4 | 2024 | 1308 | 0.170 |
Why?
| | Head and Neck Neoplasms | 2 | 2017 | 560 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 2782 | 0.170 |
Why?
| | Zebrafish | 2 | 2016 | 524 | 0.170 |
Why?
| | Autoantibodies | 5 | 2020 | 1497 | 0.170 |
Why?
| | Mutation, Missense | 2 | 2016 | 342 | 0.170 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 240 | 0.170 |
Why?
| | Receptors, Androgen | 2 | 2021 | 154 | 0.170 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 193 | 0.170 |
Why?
| | Epilepsies, Partial | 1 | 2021 | 58 | 0.170 |
Why?
| | Genotype | 8 | 2019 | 1837 | 0.170 |
Why?
| | Anxiety Disorders | 1 | 2004 | 365 | 0.170 |
Why?
| | Hyaluronan Receptors | 1 | 2021 | 104 | 0.160 |
Why?
| | Amino Acid Motifs | 2 | 2019 | 225 | 0.160 |
Why?
| | Epilepsy | 2 | 2021 | 374 | 0.160 |
Why?
| | Peptides | 4 | 2007 | 986 | 0.160 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 310 | 0.160 |
Why?
| | Pattern Recognition, Automated | 4 | 2009 | 76 | 0.160 |
Why?
| | Lymphocytes | 2 | 2023 | 395 | 0.160 |
Why?
| | RNA, Messenger | 8 | 2024 | 2847 | 0.160 |
Why?
| | Mexican Americans | 3 | 2008 | 114 | 0.160 |
Why?
| | Radiography | 1 | 2022 | 838 | 0.150 |
Why?
| | Drug Resistant Epilepsy | 1 | 2021 | 119 | 0.150 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 190 | 0.150 |
Why?
| | Androgens | 3 | 2012 | 187 | 0.150 |
Why?
| | Cross-Sectional Studies | 4 | 2026 | 5761 | 0.150 |
Why?
| | Phosphorylation | 3 | 2019 | 1761 | 0.150 |
Why?
| | Exome | 2 | 2018 | 239 | 0.150 |
Why?
| | Disease Reservoirs | 1 | 2019 | 25 | 0.150 |
Why?
| | Protein Binding | 5 | 2019 | 2261 | 0.150 |
Why?
| | Tretinoin | 1 | 2020 | 124 | 0.150 |
Why?
| | Hospital Mortality | 1 | 2024 | 975 | 0.150 |
Why?
| | Tandem Mass Spectrometry | 3 | 2014 | 573 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 872 | 0.150 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2019 | 45 | 0.150 |
Why?
| | Disease | 1 | 2019 | 98 | 0.150 |
Why?
| | Functional Neuroimaging | 1 | 2019 | 60 | 0.150 |
Why?
| | Bone Regeneration | 1 | 2019 | 27 | 0.150 |
Why?
| | Molecular Sequence Data | 4 | 2015 | 2914 | 0.150 |
Why?
| | Prognosis | 11 | 2021 | 4211 | 0.140 |
Why?
| | Disease Transmission, Infectious | 1 | 2019 | 68 | 0.140 |
Why?
| | Mice | 16 | 2025 | 18421 | 0.140 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2620 | 0.140 |
Why?
| | Radiology Information Systems | 1 | 2018 | 35 | 0.140 |
Why?
| | Artificial Intelligence | 3 | 2008 | 360 | 0.140 |
Why?
| | Pilot Projects | 2 | 2021 | 1851 | 0.140 |
Why?
| | Pituitary Gland | 2 | 2009 | 153 | 0.140 |
Why?
| | Precancerous Conditions | 1 | 2020 | 167 | 0.140 |
Why?
| | Protein Structure, Tertiary | 3 | 2012 | 857 | 0.140 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 102 | 0.140 |
Why?
| | Genetic Markers | 3 | 2015 | 338 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2019 | 67 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 482 | 0.140 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 110 | 0.140 |
Why?
| | Wilms Tumor | 1 | 2019 | 84 | 0.140 |
Why?
| | Nuclear Proteins | 2 | 2019 | 751 | 0.140 |
Why?
| | Longitudinal Studies | 5 | 2026 | 2947 | 0.140 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2024 | 104 | 0.140 |
Why?
| | Observational Studies as Topic | 1 | 2018 | 127 | 0.140 |
Why?
| | Protein Phosphatase 2 | 1 | 2018 | 41 | 0.130 |
Why?
| | Intensive Care Units | 1 | 2024 | 905 | 0.130 |
Why?
| | Pancreatic Neoplasms | 3 | 2019 | 927 | 0.130 |
Why?
| | RNA, Neoplasm | 1 | 2017 | 90 | 0.130 |
Why?
| | CD24 Antigen | 1 | 2017 | 18 | 0.130 |
Why?
| | RNA, Small Interfering | 2 | 2019 | 645 | 0.130 |
Why?
| | Genes, Neoplasm | 3 | 2007 | 26 | 0.130 |
Why?
| | Pregnancy | 5 | 2019 | 7154 | 0.130 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 99 | 0.130 |
Why?
| | DNA, Neoplasm | 1 | 2017 | 165 | 0.130 |
Why?
| | Child Health | 1 | 2019 | 154 | 0.130 |
Why?
| | Epigenomics | 1 | 2017 | 115 | 0.130 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2012 | 118 | 0.130 |
Why?
| | Osteogenesis | 1 | 2019 | 205 | 0.130 |
Why?
| | Beryllium | 1 | 2018 | 161 | 0.130 |
Why?
| | Up-Regulation | 2 | 2018 | 863 | 0.130 |
Why?
| | Antley-Bixler Syndrome Phenotype | 1 | 2016 | 1 | 0.130 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 177 | 0.130 |
Why?
| | Neoplasm Metastasis | 6 | 2019 | 704 | 0.130 |
Why?
| | Calcium Compounds | 1 | 2016 | 6 | 0.120 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2016 | 44 | 0.120 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 86 | 0.120 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 285 | 0.120 |
Why?
| | Transcription, Genetic | 7 | 2013 | 1504 | 0.120 |
Why?
| | Anesthesia Department, Hospital | 1 | 2016 | 5 | 0.120 |
Why?
| | Normal Distribution | 2 | 2014 | 22 | 0.120 |
Why?
| | Nurse Anesthetists | 1 | 2016 | 7 | 0.120 |
Why?
| | Memory, Short-Term | 1 | 2019 | 269 | 0.120 |
Why?
| | Chromosome Aberrations | 2 | 2007 | 164 | 0.120 |
Why?
| | RNA, Viral | 2 | 2024 | 690 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2018 | 169 | 0.120 |
Why?
| | Mosquito Control | 1 | 2016 | 29 | 0.120 |
Why?
| | Salivary Gland Neoplasms | 1 | 2016 | 39 | 0.120 |
Why?
| | Tumor Cells, Cultured | 5 | 2021 | 944 | 0.120 |
Why?
| | Transcription Factors | 6 | 2017 | 1735 | 0.120 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 663 | 0.120 |
Why?
| | Lymph Nodes | 1 | 2019 | 502 | 0.120 |
Why?
| | Anus Neoplasms | 1 | 2016 | 33 | 0.120 |
Why?
| | Oxides | 1 | 2016 | 51 | 0.120 |
Why?
| | ErbB Receptors | 2 | 2012 | 626 | 0.120 |
Why?
| | Health Services Research | 1 | 2019 | 395 | 0.120 |
Why?
| | Respiratory Sounds | 2 | 2007 | 106 | 0.120 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 467 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2020 | 586 | 0.120 |
Why?
| | Transcriptional Activation | 1 | 2018 | 382 | 0.120 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 32 | 0.120 |
Why?
| | Anesthesia, Obstetrical | 1 | 2016 | 30 | 0.120 |
Why?
| | Endopeptidases | 1 | 2016 | 80 | 0.120 |
Why?
| | X-Ray Diffraction | 1 | 2016 | 104 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 372 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 957 | 0.120 |
Why?
| | Berylliosis | 1 | 2018 | 193 | 0.120 |
Why?
| | Anal Canal | 1 | 2016 | 101 | 0.120 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 246 | 0.120 |
Why?
| | Heart Arrest | 1 | 2020 | 403 | 0.120 |
Why?
| | Cough | 2 | 2007 | 133 | 0.120 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 391 | 0.120 |
Why?
| | Anesthesiologists | 1 | 2016 | 63 | 0.110 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2007 | 342 | 0.110 |
Why?
| | Oleic Acid | 1 | 2015 | 42 | 0.110 |
Why?
| | Aged, 80 and over | 13 | 2022 | 8130 | 0.110 |
Why?
| | Proteolysis | 1 | 2016 | 176 | 0.110 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 315 | 0.110 |
Why?
| | Mutation | 2 | 2025 | 4106 | 0.110 |
Why?
| | Hypoglycemic Agents | 2 | 2021 | 1393 | 0.110 |
Why?
| | Parkinson Disease | 1 | 2021 | 595 | 0.110 |
Why?
| | Prevalence | 3 | 2026 | 2819 | 0.110 |
Why?
| | Schizophrenia | 1 | 2019 | 430 | 0.110 |
Why?
| | Risk | 1 | 2017 | 901 | 0.110 |
Why?
| | Air Pollution | 2 | 2017 | 326 | 0.110 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.110 |
Why?
| | Kidney Neoplasms | 1 | 2019 | 410 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 410 | 0.110 |
Why?
| | Cancer Survivors | 1 | 2019 | 309 | 0.110 |
Why?
| | Cell Differentiation | 2 | 2020 | 2045 | 0.110 |
Why?
| | Discriminant Analysis | 3 | 2020 | 37 | 0.110 |
Why?
| | Influenza Vaccines | 1 | 2019 | 524 | 0.110 |
Why?
| | Executive Function | 1 | 2019 | 455 | 0.110 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 746 | 0.110 |
Why?
| | Blood Glucose | 2 | 2022 | 2325 | 0.110 |
Why?
| | Ants | 1 | 2014 | 27 | 0.110 |
Why?
| | Colorectal Neoplasms | 3 | 2012 | 848 | 0.110 |
Why?
| | Metmyoglobin | 1 | 2014 | 2 | 0.100 |
Why?
| | Catalysis | 2 | 2012 | 326 | 0.100 |
Why?
| | Time Factors | 5 | 2016 | 7068 | 0.100 |
Why?
| | Sulfonic Acids | 1 | 2014 | 17 | 0.100 |
Why?
| | Treatment Failure | 1 | 2015 | 363 | 0.100 |
Why?
| | Chromatography, Ion Exchange | 1 | 2014 | 56 | 0.100 |
Why?
| | Chromatography, Affinity | 1 | 2014 | 88 | 0.100 |
Why?
| | Antiprotozoal Agents | 1 | 2013 | 15 | 0.100 |
Why?
| | Chromatography, Gel | 1 | 2014 | 129 | 0.100 |
Why?
| | Survival Rate | 4 | 2019 | 2035 | 0.100 |
Why?
| | Benzothiazoles | 1 | 2014 | 40 | 0.100 |
Why?
| | Amphotericin B | 1 | 2013 | 37 | 0.100 |
Why?
| | Free Radical Scavengers | 1 | 2014 | 86 | 0.100 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2015 | 230 | 0.100 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 517 | 0.100 |
Why?
| | Vaccines, Synthetic | 2 | 2025 | 140 | 0.100 |
Why?
| | Cell Line, Tumor | 7 | 2019 | 3609 | 0.100 |
Why?
| | Odds Ratio | 3 | 2020 | 1057 | 0.100 |
Why?
| | Brain Diseases | 1 | 2015 | 152 | 0.100 |
Why?
| | Crystallization | 1 | 2014 | 138 | 0.100 |
Why?
| | Embryonic Stem Cells | 1 | 2014 | 130 | 0.100 |
Why?
| | Trans-Activators | 3 | 2020 | 398 | 0.100 |
Why?
| | Influenza, Human | 1 | 2019 | 611 | 0.100 |
Why?
| | Cohort Studies | 8 | 2017 | 5862 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2023 | 5317 | 0.090 |
Why?
| | Estradiol | 2 | 2014 | 538 | 0.090 |
Why?
| | Rhodium | 1 | 2012 | 2 | 0.090 |
Why?
| | Interleukin-2 | 2 | 2025 | 447 | 0.090 |
Why?
| | Positron-Emission Tomography | 2 | 2024 | 318 | 0.090 |
Why?
| | Androstadienes | 1 | 2012 | 79 | 0.090 |
Why?
| | Nucleic Acid Amplification Techniques | 2 | 2022 | 39 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2019 | 1270 | 0.090 |
Why?
| | Influenza A Virus, H5N1 Subtype | 1 | 2011 | 10 | 0.090 |
Why?
| | Silver | 1 | 2012 | 37 | 0.090 |
Why?
| | Least-Squares Analysis | 2 | 2020 | 77 | 0.090 |
Why?
| | Repressor Proteins | 2 | 2007 | 432 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2025 | 945 | 0.090 |
Why?
| | Gene Silencing | 3 | 2007 | 202 | 0.090 |
Why?
| | Transcription Factor Pit-1 | 1 | 2011 | 27 | 0.090 |
Why?
| | Motion | 1 | 2012 | 100 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2024 | 991 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 945 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2020 | 1170 | 0.090 |
Why?
| | Hypopituitarism | 1 | 2011 | 16 | 0.090 |
Why?
| | Otx Transcription Factors | 1 | 2011 | 15 | 0.090 |
Why?
| | Heme | 1 | 2012 | 86 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2020 | 1170 | 0.090 |
Why?
| | Brucella suis | 1 | 2011 | 1 | 0.090 |
Why?
| | Brucellosis | 1 | 2011 | 2 | 0.090 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2017 | 97 | 0.090 |
Why?
| | Caspase 2 | 1 | 2011 | 12 | 0.090 |
Why?
| | Immunity, Innate | 2 | 2025 | 853 | 0.090 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2011 | 100 | 0.090 |
Why?
| | Prostatic Intraepithelial Neoplasia | 2 | 2008 | 9 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 699 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2022 | 345 | 0.080 |
Why?
| | Cattle | 1 | 2014 | 1004 | 0.080 |
Why?
| | Catalytic Domain | 1 | 2012 | 226 | 0.080 |
Why?
| | Chemoradiotherapy | 3 | 2017 | 235 | 0.080 |
Why?
| | Lipid Bilayers | 1 | 2012 | 103 | 0.080 |
Why?
| | Pharmacogenetics | 1 | 2012 | 170 | 0.080 |
Why?
| | Age Factors | 3 | 2020 | 3288 | 0.080 |
Why?
| | Chemokines | 1 | 2011 | 224 | 0.080 |
Why?
| | Neoplasm Invasiveness | 4 | 2017 | 515 | 0.080 |
Why?
| | Pediatrics | 1 | 2019 | 1080 | 0.080 |
Why?
| | Lung | 2 | 2023 | 4143 | 0.080 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2019 | 878 | 0.080 |
Why?
| | Vaccination | 1 | 2019 | 1414 | 0.080 |
Why?
| | Zalcitabine | 1 | 2010 | 2 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 157 | 0.080 |
Why?
| | Didanosine | 1 | 2010 | 13 | 0.080 |
Why?
| | Nonlinear Dynamics | 1 | 2010 | 94 | 0.080 |
Why?
| | Mental Disorders | 1 | 2019 | 1127 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1096 | 0.080 |
Why?
| | Phosphoglycerate Kinase | 1 | 2009 | 2 | 0.080 |
Why?
| | Antibody Formation | 2 | 2007 | 294 | 0.080 |
Why?
| | Rural Population | 1 | 2014 | 638 | 0.080 |
Why?
| | Activities of Daily Living | 2 | 2003 | 435 | 0.080 |
Why?
| | Sarcosine | 1 | 2009 | 10 | 0.070 |
Why?
| | Decision Trees | 2 | 2020 | 81 | 0.070 |
Why?
| | CpG Islands | 2 | 2023 | 167 | 0.070 |
Why?
| | Autoimmunity | 2 | 2025 | 925 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2016 | 946 | 0.070 |
Why?
| | Retinitis Pigmentosa | 1 | 2008 | 20 | 0.070 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2010 | 129 | 0.070 |
Why?
| | Peptide Library | 2 | 2007 | 95 | 0.070 |
Why?
| | Genes, Recessive | 1 | 2008 | 78 | 0.070 |
Why?
| | Acculturation | 1 | 2008 | 53 | 0.070 |
Why?
| | Homozygote | 1 | 2008 | 201 | 0.070 |
Why?
| | Psoriasis | 1 | 2009 | 110 | 0.070 |
Why?
| | Complex Mixtures | 1 | 2007 | 12 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2024 | 16755 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2024 | 684 | 0.070 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2007 | 35 | 0.070 |
Why?
| | Anti-HIV Agents | 1 | 2015 | 864 | 0.070 |
Why?
| | Confidence Intervals | 1 | 2008 | 330 | 0.070 |
Why?
| | Uncertainty | 1 | 2008 | 140 | 0.070 |
Why?
| | Blindness | 1 | 2008 | 50 | 0.070 |
Why?
| | Models, Molecular | 2 | 2019 | 1600 | 0.070 |
Why?
| | Mice, Nude | 2 | 2021 | 692 | 0.070 |
Why?
| | Xenopus | 1 | 2007 | 86 | 0.070 |
Why?
| | Proteins | 2 | 2003 | 1023 | 0.070 |
Why?
| | Glaucoma | 1 | 2010 | 250 | 0.070 |
Why?
| | Leisure Activities | 1 | 2007 | 30 | 0.060 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 395 | 0.060 |
Why?
| | Antibodies, Neoplasm | 1 | 2007 | 34 | 0.060 |
Why?
| | Genes, myc | 1 | 2007 | 51 | 0.060 |
Why?
| | Pituitary Neoplasms | 1 | 2009 | 191 | 0.060 |
Why?
| | Decision Theory | 1 | 2006 | 1 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1322 | 0.060 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 333 | 0.060 |
Why?
| | Nails | 1 | 2007 | 13 | 0.060 |
Why?
| | Self Concept | 1 | 2009 | 253 | 0.060 |
Why?
| | Socioeconomic Factors | 2 | 2008 | 1327 | 0.060 |
Why?
| | Information Storage and Retrieval | 1 | 2007 | 121 | 0.060 |
Why?
| | Nepal | 2 | 2016 | 32 | 0.060 |
Why?
| | Genome, Human | 4 | 2016 | 429 | 0.060 |
Why?
| | Genome, Bacterial | 2 | 2006 | 155 | 0.060 |
Why?
| | Genes, MHC Class II | 1 | 2006 | 77 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3838 | 0.060 |
Why?
| | Pharynx | 1 | 2006 | 61 | 0.060 |
Why?
| | DNA, Bacterial | 2 | 2006 | 341 | 0.060 |
Why?
| | Haemophilus Infections | 1 | 2006 | 40 | 0.060 |
Why?
| | Apoptosis | 3 | 2021 | 2446 | 0.060 |
Why?
| | Serine Endopeptidases | 1 | 2007 | 128 | 0.060 |
Why?
| | Haemophilus influenzae | 1 | 2006 | 62 | 0.060 |
Why?
| | Arsenic | 1 | 2007 | 64 | 0.060 |
Why?
| | Structure-Activity Relationship | 1 | 2007 | 567 | 0.060 |
Why?
| | GATA3 Transcription Factor | 1 | 2005 | 24 | 0.060 |
Why?
| | Death Certificates | 1 | 2006 | 32 | 0.060 |
Why?
| | Calibration | 2 | 2022 | 153 | 0.060 |
Why?
| | Biotinylation | 1 | 2005 | 37 | 0.060 |
Why?
| | Cell Cycle Proteins | 2 | 2007 | 636 | 0.060 |
Why?
| | Molecular Mimicry | 1 | 2005 | 41 | 0.060 |
Why?
| | Nephrocalcinosis | 1 | 2025 | 13 | 0.060 |
Why?
| | Quantitative Trait Loci | 1 | 2008 | 367 | 0.060 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2005 | 51 | 0.060 |
Why?
| | Hydrogen Bonding | 1 | 2005 | 166 | 0.060 |
Why?
| | STAT5 Transcription Factor | 1 | 2025 | 53 | 0.060 |
Why?
| | Diabetic Retinopathy | 1 | 2008 | 206 | 0.060 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2005 | 55 | 0.060 |
Why?
| | United States | 7 | 2018 | 15602 | 0.060 |
Why?
| | Absorptiometry, Photon | 1 | 2026 | 277 | 0.060 |
Why?
| | Protein Interaction Mapping | 1 | 2005 | 102 | 0.060 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2005 | 392 | 0.060 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2006 | 366 | 0.050 |
Why?
| | Family Characteristics | 2 | 2016 | 199 | 0.050 |
Why?
| | Interleukin-15 | 1 | 2025 | 99 | 0.050 |
Why?
| | Mobile Health Units | 1 | 2024 | 20 | 0.050 |
Why?
| | Disease-Free Survival | 3 | 2017 | 767 | 0.050 |
Why?
| | Environmental Pollutants | 1 | 2007 | 163 | 0.050 |
Why?
| | Area Under Curve | 2 | 2020 | 333 | 0.050 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 69 | 0.050 |
Why?
| | Protein Structure, Secondary | 1 | 2005 | 362 | 0.050 |
Why?
| | Linkage Disequilibrium | 1 | 2005 | 248 | 0.050 |
Why?
| | Poisson Distribution | 1 | 2004 | 75 | 0.050 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2004 | 17 | 0.050 |
Why?
| | Polymerase Chain Reaction | 3 | 2017 | 1057 | 0.050 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2004 | 20 | 0.050 |
Why?
| | Bed Occupancy | 1 | 2024 | 16 | 0.050 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2004 | 49 | 0.050 |
Why?
| | Sputum | 1 | 2006 | 314 | 0.050 |
Why?
| | Asthma | 2 | 2007 | 1915 | 0.050 |
Why?
| | Lipids | 1 | 2009 | 699 | 0.050 |
Why?
| | Culture Techniques | 1 | 2004 | 67 | 0.050 |
Why?
| | Bacterial Typing Techniques | 1 | 2004 | 44 | 0.050 |
Why?
| | Cancer Vaccines | 1 | 2005 | 167 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2020 | 376 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2023 | 15 | 0.050 |
Why?
| | Pedigree | 2 | 2019 | 512 | 0.050 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2004 | 61 | 0.050 |
Why?
| | Environmental Monitoring | 1 | 2007 | 377 | 0.050 |
Why?
| | Genetic Heterogeneity | 1 | 2004 | 63 | 0.050 |
Why?
| | Body Mass Index | 2 | 2016 | 2439 | 0.050 |
Why?
| | Polybrominated Biphenyls | 1 | 2003 | 2 | 0.050 |
Why?
| | Personality Inventory | 1 | 2004 | 134 | 0.050 |
Why?
| | Genetics, Population | 1 | 2005 | 213 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2023 | 113 | 0.050 |
Why?
| | Otitis Media | 1 | 2006 | 178 | 0.050 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2009 | 904 | 0.050 |
Why?
| | Pandemics | 2 | 2023 | 1675 | 0.050 |
Why?
| | Expressed Sequence Tags | 1 | 2003 | 44 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2020 | 327 | 0.050 |
Why?
| | Cause of Death | 1 | 2006 | 461 | 0.050 |
Why?
| | Wnt Proteins | 2 | 2020 | 136 | 0.050 |
Why?
| | Signal-To-Noise Ratio | 1 | 2023 | 73 | 0.050 |
Why?
| | Bile Ducts | 1 | 2003 | 64 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2024 | 287 | 0.050 |
Why?
| | Resistance Training | 1 | 2026 | 177 | 0.050 |
Why?
| | Down-Regulation | 1 | 2025 | 641 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 89 | 0.050 |
Why?
| | Macrophages | 1 | 2011 | 1508 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2005 | 328 | 0.050 |
Why?
| | Hyperplasia | 1 | 2003 | 174 | 0.050 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2023 | 135 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 101 | 0.050 |
Why?
| | Antibodies, Monoclonal | 2 | 2012 | 1522 | 0.050 |
Why?
| | Artifacts | 1 | 2023 | 139 | 0.050 |
Why?
| | Health Policy | 1 | 2026 | 390 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 856 | 0.050 |
Why?
| | Breast | 1 | 2003 | 162 | 0.050 |
Why?
| | Biguanides | 1 | 2022 | 10 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2026 | 1402 | 0.050 |
Why?
| | Selection Bias | 1 | 2022 | 38 | 0.050 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2023 | 135 | 0.050 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2023 | 142 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 722 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2004 | 251 | 0.050 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2025 | 392 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2025 | 473 | 0.050 |
Why?
| | Complement System Proteins | 1 | 2005 | 315 | 0.050 |
Why?
| | Sarcoma, Ewing | 1 | 2003 | 101 | 0.050 |
Why?
| | Benchmarking | 1 | 2023 | 181 | 0.050 |
Why?
| | Lymphoma, B-Cell | 1 | 2003 | 136 | 0.050 |
Why?
| | Dendritic Cells | 1 | 2025 | 495 | 0.050 |
Why?
| | Hospitalization | 2 | 2024 | 2340 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2008 | 1182 | 0.040 |
Why?
| | Yeasts | 1 | 2002 | 51 | 0.040 |
Why?
| | Genes, BRCA2 | 1 | 2002 | 32 | 0.040 |
Why?
| | Evaluation Studies as Topic | 1 | 2002 | 169 | 0.040 |
Why?
| | Genes, BRCA1 | 1 | 2002 | 44 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 6032 | 0.040 |
Why?
| | Faculty, Medical | 1 | 2025 | 294 | 0.040 |
Why?
| | Seasons | 1 | 2024 | 547 | 0.040 |
Why?
| | Epithelial Cells | 2 | 2008 | 1128 | 0.040 |
Why?
| | Antigens, Protozoan | 1 | 2021 | 32 | 0.040 |
Why?
| | Health Care Surveys | 2 | 2016 | 535 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2023 | 421 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2030 | 0.040 |
Why?
| | Citrullination | 1 | 2020 | 13 | 0.040 |
Why?
| | Japan | 1 | 2021 | 141 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2005 | 511 | 0.040 |
Why?
| | Genetic Testing | 1 | 2004 | 475 | 0.040 |
Why?
| | Somatostatin-Secreting Cells | 1 | 2020 | 3 | 0.040 |
Why?
| | Drosophila Proteins | 1 | 2002 | 206 | 0.040 |
Why?
| | Leadership | 1 | 2025 | 404 | 0.040 |
Why?
| | Milk, Human | 1 | 2022 | 171 | 0.040 |
Why?
| | Receptors, Retinoic Acid | 1 | 2020 | 43 | 0.040 |
Why?
| | Somatostatin | 1 | 2020 | 55 | 0.040 |
Why?
| | Human Embryonic Stem Cells | 1 | 2020 | 26 | 0.040 |
Why?
| | Citalopram | 1 | 2020 | 33 | 0.040 |
Why?
| | Immunity, Cellular | 1 | 2022 | 273 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2024 | 899 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 580 | 0.040 |
Why?
| | Policy | 1 | 2021 | 147 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2026 | 6004 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 561 | 0.040 |
Why?
| | Support Vector Machine | 1 | 2020 | 36 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2021 | 279 | 0.040 |
Why?
| | Polycomb Repressive Complex 2 | 3 | 2007 | 82 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2020 | 234 | 0.040 |
Why?
| | Immunoblotting | 3 | 2005 | 307 | 0.040 |
Why?
| | Allosteric Regulation | 1 | 2019 | 91 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2020 | 140 | 0.040 |
Why?
| | Nanog Homeobox Protein | 1 | 2019 | 14 | 0.040 |
Why?
| | Disease Vectors | 1 | 2019 | 15 | 0.040 |
Why?
| | Polymethyl Methacrylate | 1 | 2019 | 22 | 0.040 |
Why?
| | Cognition Disorders | 1 | 2003 | 542 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 351 | 0.040 |
Why?
| | Leprosy | 1 | 2019 | 25 | 0.040 |
Why?
| | Schizophrenic Psychology | 1 | 2019 | 95 | 0.040 |
Why?
| | Binding Sites | 2 | 2017 | 1312 | 0.040 |
Why?
| | Skin | 2 | 2017 | 760 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 726 | 0.040 |
Why?
| | Quality of Life | 2 | 2009 | 3141 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2025 | 4553 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 791 | 0.040 |
Why?
| | Breast Feeding | 1 | 2022 | 444 | 0.040 |
Why?
| | SEER Program | 1 | 2019 | 222 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 531 | 0.040 |
Why?
| | Virulence | 2 | 2011 | 271 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2023 | 889 | 0.030 |
Why?
| | Malaria | 1 | 2019 | 72 | 0.030 |
Why?
| | Mice, SCID | 1 | 2019 | 377 | 0.030 |
Why?
| | Prostatic Hyperplasia | 2 | 2008 | 40 | 0.030 |
Why?
| | Epigenesis, Genetic | 2 | 2017 | 684 | 0.030 |
Why?
| | Autoantigens | 1 | 2020 | 429 | 0.030 |
Why?
| | Seizures | 1 | 2021 | 454 | 0.030 |
Why?
| | Xenodiagnosis | 1 | 2017 | 2 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2020 | 511 | 0.030 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 246 | 0.030 |
Why?
| | DNA, Protozoan | 1 | 2017 | 32 | 0.030 |
Why?
| | Protein Domains | 1 | 2019 | 313 | 0.030 |
Why?
| | Protein Stability | 1 | 2018 | 177 | 0.030 |
Why?
| | Kidney | 1 | 2025 | 1483 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2020 | 3120 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 52 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 615 | 0.030 |
Why?
| | Taiwan | 2 | 2007 | 45 | 0.030 |
Why?
| | Databases, Protein | 2 | 2007 | 91 | 0.030 |
Why?
| | Michigan | 2 | 2007 | 135 | 0.030 |
Why?
| | After-Hours Care | 1 | 2016 | 15 | 0.030 |
Why?
| | Enzyme Stability | 1 | 2016 | 73 | 0.030 |
Why?
| | Tissue Scaffolds | 1 | 2019 | 221 | 0.030 |
Why?
| | Analgesia, Patient-Controlled | 1 | 2016 | 16 | 0.030 |
Why?
| | Sterilization, Tubal | 1 | 2016 | 17 | 0.030 |
Why?
| | Platelet Count | 1 | 2016 | 89 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 141 | 0.030 |
Why?
| | Population Density | 1 | 2016 | 101 | 0.030 |
Why?
| | Fibroblasts | 1 | 2002 | 1035 | 0.030 |
Why?
| | Live Birth | 1 | 2016 | 68 | 0.030 |
Why?
| | Prostate | 2 | 2008 | 157 | 0.030 |
Why?
| | Prostate-Specific Antigen | 2 | 2008 | 158 | 0.030 |
Why?
| | International Cooperation | 1 | 2016 | 197 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2019 | 832 | 0.030 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2016 | 98 | 0.030 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 2 | 2007 | 57 | 0.030 |
Why?
| | Survivors | 1 | 2019 | 513 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 409 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 304 | 0.030 |
Why?
| | Tuberculosis | 1 | 2019 | 287 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 748 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 2016 | 194 | 0.030 |
Why?
| | Genes, Bacterial | 2 | 2006 | 166 | 0.030 |
Why?
| | Family | 1 | 2019 | 692 | 0.030 |
Why?
| | Gene Regulatory Networks | 2 | 2007 | 322 | 0.030 |
Why?
| | Rats | 1 | 2003 | 5609 | 0.030 |
Why?
| | Epistasis, Genetic | 1 | 2015 | 65 | 0.030 |
Why?
| | Cognition | 1 | 2003 | 1252 | 0.030 |
Why?
| | Cell Movement | 1 | 2019 | 973 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2016 | 140 | 0.030 |
Why?
| | Skin Neoplasms | 1 | 2002 | 860 | 0.030 |
Why?
| | Genes, Essential | 1 | 2014 | 23 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2019 | 1122 | 0.030 |
Why?
| | Data Collection | 2 | 2007 | 636 | 0.030 |
Why?
| | Cesarean Section | 1 | 2016 | 224 | 0.030 |
Why?
| | GATA1 Transcription Factor | 1 | 2014 | 18 | 0.030 |
Why?
| | Particulate Matter | 1 | 2017 | 342 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2018 | 352 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2014 | 104 | 0.030 |
Why?
| | Hospitals, Public | 1 | 2013 | 29 | 0.030 |
Why?
| | Demography | 1 | 2014 | 289 | 0.030 |
Why?
| | Methylation | 1 | 2014 | 243 | 0.030 |
Why?
| | North America | 1 | 2014 | 309 | 0.020 |
Why?
| | Hospitals, Rural | 1 | 2013 | 44 | 0.020 |
Why?
| | Organ Specificity | 1 | 2014 | 308 | 0.020 |
Why?
| | Host-Parasite Interactions | 1 | 2014 | 112 | 0.020 |
Why?
| | Receptors, Estrogen | 2 | 2007 | 466 | 0.020 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 179 | 0.020 |
Why?
| | Species Specificity | 1 | 2014 | 573 | 0.020 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2013 | 92 | 0.020 |
Why?
| | Cell Line | 2 | 2009 | 2906 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 427 | 0.020 |
Why?
| | Cytokines | 1 | 2020 | 2093 | 0.020 |
Why?
| | Sequence Analysis, DNA | 2 | 2006 | 828 | 0.020 |
Why?
| | Schizosaccharomyces | 1 | 2013 | 95 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2266 | 0.020 |
Why?
| | Carboplatin | 1 | 2012 | 160 | 0.020 |
Why?
| | Hydrogen | 1 | 2012 | 73 | 0.020 |
Why?
| | Cetuximab | 1 | 2012 | 113 | 0.020 |
Why?
| | Methane | 1 | 2012 | 51 | 0.020 |
Why?
| | Databases, Nucleic Acid | 1 | 2012 | 40 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 779 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 256 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 320 | 0.020 |
Why?
| | Quinazolines | 1 | 2012 | 266 | 0.020 |
Why?
| | Prospective Studies | 3 | 2009 | 7900 | 0.020 |
Why?
| | Self Report | 1 | 2014 | 864 | 0.020 |
Why?
| | Electrophoresis | 1 | 2009 | 30 | 0.020 |
Why?
| | Hospitals | 1 | 2014 | 695 | 0.020 |
Why?
| | Pituitary Hormones | 1 | 2009 | 16 | 0.020 |
Why?
| | Depression | 1 | 2019 | 1520 | 0.020 |
Why?
| | Mass Screening | 1 | 2018 | 1325 | 0.020 |
Why?
| | Sarcosine Dehydrogenase | 1 | 2009 | 1 | 0.020 |
Why?
| | Glycine N-Methyltransferase | 1 | 2009 | 4 | 0.020 |
Why?
| | Bone Morphogenetic Protein Receptors, Type I | 1 | 2009 | 10 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 387 | 0.020 |
Why?
| | Insulin | 1 | 2020 | 2502 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1751 | 0.020 |
Why?
| | Ophthalmoscopy | 1 | 2008 | 38 | 0.020 |
Why?
| | Electroretinography | 1 | 2008 | 50 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 396 | 0.020 |
Why?
| | Consanguinity | 1 | 2008 | 49 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2011 | 318 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 306 | 0.020 |
Why?
| | Gene Library | 1 | 2009 | 126 | 0.020 |
Why?
| | Golgi Apparatus | 1 | 2008 | 102 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 2220 | 0.020 |
Why?
| | Genes | 1 | 2008 | 226 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 2007 | 28 | 0.020 |
Why?
| | Keratinocytes | 1 | 2009 | 249 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 337 | 0.020 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 2007 | 3 | 0.020 |
Why?
| | Chromosomes, Human, 6-12 and X | 1 | 2007 | 3 | 0.020 |
Why?
| | Polycomb-Group Proteins | 1 | 2007 | 36 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 516 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2007 | 30 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2007 | 44 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1938 | 0.020 |
Why?
| | Feedback | 1 | 2008 | 182 | 0.020 |
Why?
| | Bacteriophage T7 | 1 | 2007 | 5 | 0.020 |
Why?
| | Seaweed | 1 | 2007 | 2 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 256 | 0.020 |
Why?
| | Agaricales | 1 | 2007 | 4 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2009 | 454 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 394 | 0.020 |
Why?
| | Subtraction Technique | 1 | 2007 | 25 | 0.020 |
Why?
| | Data Display | 1 | 2007 | 20 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2007 | 44 | 0.020 |
Why?
| | Autophagy-Related Proteins | 1 | 2007 | 47 | 0.020 |
Why?
| | Seafood | 1 | 2007 | 26 | 0.020 |
Why?
| | Food Contamination | 1 | 2007 | 55 | 0.020 |
Why?
| | Oryza | 1 | 2007 | 32 | 0.020 |
Why?
| | Television | 1 | 2007 | 72 | 0.020 |
Why?
| | Sequence Analysis, Protein | 1 | 2006 | 33 | 0.020 |
Why?
| | Oxygen | 1 | 2012 | 1000 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2013 | 1377 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 93 | 0.020 |
Why?
| | Tomography, Optical Coherence | 1 | 2008 | 262 | 0.020 |
Why?
| | Lymphoma | 1 | 2008 | 234 | 0.020 |
Why?
| | Managed Care Programs | 1 | 2007 | 135 | 0.020 |
Why?
| | Fishes | 1 | 2007 | 110 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 2006 | 189 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 1133 | 0.020 |
Why?
| | Ear, Middle | 1 | 2006 | 84 | 0.020 |
Why?
| | Water Supply | 1 | 2007 | 88 | 0.020 |
Why?
| | Urban Health | 1 | 2006 | 95 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1223 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 982 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1355 | 0.010 |
Why?
| | Drug Design | 1 | 2007 | 175 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2009 | 524 | 0.010 |
Why?
| | Fibrocystic Breast Disease | 1 | 2005 | 2 | 0.010 |
Why?
| | Databases as Topic | 1 | 2005 | 68 | 0.010 |
Why?
| | Base Composition | 1 | 2005 | 79 | 0.010 |
Why?
| | E2F Transcription Factors | 1 | 2005 | 76 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2005 | 50 | 0.010 |
Why?
| | DNA Probes | 1 | 2005 | 57 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2007 | 384 | 0.010 |
Why?
| | Bone Morphogenetic Protein Receptors | 1 | 2004 | 6 | 0.010 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2004 | 44 | 0.010 |
Why?
| | Autopsy | 1 | 2004 | 93 | 0.010 |
Why?
| | Smad Proteins | 1 | 2004 | 42 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 2004 | 56 | 0.010 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2004 | 41 | 0.010 |
Why?
| | Random Allocation | 1 | 2005 | 364 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 2005 | 202 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2007 | 439 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2004 | 148 | 0.010 |
Why?
| | Receptors, Progesterone | 1 | 2005 | 353 | 0.010 |
Why?
| | Retinal Diseases | 1 | 2004 | 97 | 0.010 |
Why?
| | Selection, Genetic | 1 | 2005 | 258 | 0.010 |
Why?
| | Spermine | 1 | 2002 | 30 | 0.010 |
Why?
| | Spermidine | 1 | 2002 | 18 | 0.010 |
Why?
| | Genes, Tumor Suppressor | 1 | 2002 | 90 | 0.010 |
Why?
| | Overweight | 1 | 2007 | 598 | 0.010 |
Why?
| | Internet | 1 | 2007 | 699 | 0.010 |
Why?
| | Adenosine Monophosphate | 1 | 2002 | 83 | 0.010 |
Why?
| | California | 1 | 2003 | 464 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 184 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 221 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 632 | 0.010 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2003 | 525 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 628 | 0.010 |
Why?
| | Comorbidity | 1 | 2006 | 1638 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 952 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2006 | 928 | 0.010 |
Why?
| | RNA | 1 | 2005 | 940 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 2097 | 0.010 |
Why?
| | Stroke | 1 | 2003 | 1219 | 0.010 |
Why?
| | Aging | 1 | 2003 | 1968 | 0.010 |
Why?
|
|
Ghosh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|